Screener
Travere Therapeutics, Inc. TVTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss from continuing operations | (36,602) | (41,226) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 25,212 | 12,802 |
| Share based compensation | 16,146 | 11,492 |
| Other | (4) | (1,569) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (7,225) | (7,204) |
| Inventory | (742) | 3,664 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s stock-based comp?
- Travere Therapeutics, Inc. (TVTX) reported stock-based comp of $16.15M in Q1 2026.
- How has Travere Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Travere Therapeutics, Inc.'s stock-based comp increased by 40.5% year-over-year, from $11.49M to $16.15M.
- What is the long-term trend for Travere Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s stock-based comp has grown at a 11.0% compound annual growth rate (CAGR), from $29.57M to $44.87M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Travere Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude